News, Press Release James McIlroy News, Press Release James McIlroy

EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome

122 patients with moderate to severe irritable bowel syndrome (IBS) were recruited to EnteroBiotix’s Phase 2 TrIuMPH trial assessing EBX-102-02. EnteroBiotix completed enrolment ahead of its planned schedule, dosing 62 participants with constipation predominant IBS and 60 participants with diarrhoea predominant IBS

Read More
News, Press Release James McIlroy News, Press Release James McIlroy

EnteroBiotix receives MHRA MIA (IMP) licensure of state-of-the-art GMP manufacturing facility for producing microbiome therapeutics

EnteroBiotix today announced that it has been granted a Manufacturer’s licence for Investigational Medicinal Products (IMP) by the Medicines and Healthcare Products Regulatory Agency (MHRA) to manufacture microbiome product candidates for clinical trials. The facility also incorporates an in-house QC hub and analytical department.

Read More

Find out more about our donor programme. Visit Number2.org